Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P‐glycoprotein–cytochrome P450 3A4 dual substrates-Reference-Cited by-同舟云学术

Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P‐glycoprotein–cytochrome P450 3A4 dual substrates

Published:2021-11-02 Issue:12 Volume:10 Page:1485-1496
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacom & Syst Pharma

Author:

Pan Xian¹^ORCID,Yamazaki Shinji²^ORCID,Neuhoff Sibylle¹^ORCID,Zhang Mian¹^ORCID,Pilla Reddy Venkatesh³⁴^ORCID

Affiliation:

1. Simcyp Division Certara UK Limited Sheffield UK

2. Pharmacokinetics, Dynamics & Metabolism Pfizer Worldwide Research & Development San Diego California USA

3. Modelling and Simulation, Early Oncolog, Oncology R&D AstraZeneca Cambridge UK

4. Clinical Pharmacology and Pharmacometrics, Biopharmaceuticals R&D AstraZeneca Cambridge UK

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12717

Reference50 articles.

1. Physiologically based pharmacokinetic modeling in regulatory decision-making at the European Medicines Agency

2. Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making

3. Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018‐2019 Submissions to the US FDA's Office of Clinical Pharmacology

4. PBPK modeling to predict drug‐drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction

5. Physiologically‐Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug–Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Trial Data-Driven Risk Assessment of Drug–Drug Interactions: A Rapid and Accurate Decision-Making Tool;Clinical Pharmacokinetics;2024-08

2. Understanding CYP3A4 and P‐gp mediated drug–drug interactions through PBPK modeling – Case example of pralsetinib;CPT: Pharmacometrics & Systems Pharmacology;2024-03-13

3. Assessment of Quinidine‐Induced Torsades de Pointes Risks Using a Whole‐Body Physiologically Based Pharmacokinetic Model Linked to Cardiac Ionic Current Inhibition;Clinical Pharmacology & Therapeutics;2024-01-07

4. Tiered approach to evaluate the CYP3A victim and perpetrator drug–drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling;CPT: Pharmacometrics & Systems Pharmacology;2023-03-10

5. Therapeutic drug monitoring in optimizing tuberculosis treatment outcomes: A review on the first-line four-drug standard treatment regimen;Saudi Journal of Clinical Pharmacy;2023